Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSQ-004EX in Advanced Solid Tumors
NCT06598371Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2024
- Primary completion
- Aug 2039
- Modality
- CRISPR-Cas9, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of KSQ-004EX in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
KSQ-004EX
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06598371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598371.